CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Amphotericin B liposome for injection
Drug: AmBisome®

First Posted Date: 2021-08-06

Last Posted Date: 2021-08-06

Lead Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT04993222

Locations: 🇨🇳
Wuhan Medical Treatment Center, Wuhan, Hubei, China

Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients

Not Applicable

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Daunorubicin Cytarabine liposome for injection
Drug: Vyxeos、Daunorubicin Cytarabine liposome for injection

First Posted Date: 2021-06-09

Last Posted Date: 2021-06-09

Lead Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04920500

Locations: 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy